Research programme: selective androgen receptor modulators - Radius Health

Drug Profile

Research programme: selective androgen receptor modulators - Radius Health

Alternative Names: RAD-140

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator Radius
  • Developer Radius; Radius Health Inc.
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer
  • No development reported Muscular atrophy; Osteoporosis

Most Recent Events

  • 24 Feb 2017 Radius Health has patent protection for RAD 140 in USA, Australia, Canada, Europe, Japan and Mexico (Radius Health's form 10-K, filed in February 2017)
  • 24 Feb 2017 Radius Health has patents pending for RAD 140 in Brazil and India (Radius Health's form 10-K, filed in February 2017)
  • 23 Feb 2017 Radius plans a phase I trial for Breast Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top